anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods and compositions are provided for controlling cell distribution within an implantable bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the bioartificial organ with extracellular matrix molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination. The bioartificial organ typically has a semipermeable membrane encapsulating a cell-containing core, and is preferably immunoisolatory. Cells can be grown on microcarriers and then loaded into the bioartificial organ. The microcarriers may be coated with an extracellular matrix component such as collagen to cause decreased cell proliferation or increased cell differentiation. Microcarriers containing cells can be suspended in a proliferation inhibiting hydrogel matrix prior to encapsulation.
The invention related to pharmacy industry, and relates to a cataplasm substrate with a high-drug-load characteristic. The substrate comprises components of, by mass: 4-6 parts of carbomer, 4-6 parts of sodium polyacrylate, 0.8-1.2 parts of gelatin, 15-18 parts of kaolin, 0.8-1.2 parts of polyvinyl pyrrolidone (PVPP), 0.07-0.13 parts of aluminum glycinate, 0.015-0.02 parts of tartrate, 8-12 parts of triethanolamine, 40-60 parts of glycerin, and 40-60 parts of distilled water. A processing process of the substrate is mild and environment-friendly. With the processing process, active components of medicines can be well preserved. The drug-load of the substrate is high, and the range of optional medicines is wide. Also, compared to other cataplasm substrates, the substrate provided by the invention is advantaged in heat resistance and sweat corrosion resistance.
BACKGROUND: Syphilis incidence is increasing among reproductive-aged women, and previous sexually transmitted infections (STIs) are a risk factor for subsequent STIs. This study aimed to determine syphilis incidence after a chlamydia, gonorrhea, or HIV diagnosis, and identify characteristics associated with higher syphilis incidence rates among reproductive-aged women in 1 mid-Atlantic city.
METHODS: A retrospective cohort of 85,113 chlamydia, gonorrhea, and HIV diagnoses occurring between 2009 and 2021 and among women aged 13 to 50 years was constructed using public health surveillance data. Cumulative incidence curves were estimated to examine time to early syphilis (i.e., primary, secondary, or early latent) diagnosis, and multivariable analyses determined incidence rate ratios by age (<25 vs. ≥25 years) and number of prior STI diagnoses (0 vs. ≥1) during the study period, stratified by STI.
RESULTS: There were 85,113 reportable STI diagnoses and 646 syphilis diagnoses in the cohort. Approximately 1 of 150 chlamydia, 1 of 100 gonorrhea, and 1 of 50 HIV diagnoses were followed by a syphilis diagnosis within 5 years. Cumulative incidence of syphilis differed significantly by STI diagnosis ( P < 0.001). In multivariable analysis, syphilis incidence rates were higher among women diagnosed with ≥1 (vs. 0) prior STI regardless of STI type ( P < 0.05) and among women ≥25 (vs. <25) years old diagnosed with gonorrhea ( P < 0.05).
CONCLUSIONS: There were significant differences in syphilis incidence by prior STI type, number of STIs, and age. Our data support targeted screening for syphilis among women with a history of STIs, parwomen with ≥1 prior STI diagnosis, and older women diagnosed with gonorrhea.
Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
The Ultra-Technekow ™V4 Generator is prepared with fission-produced molybdenum Mo-99 adsorbed onto alumina in a column shielded by lead, tungsten, or depleted uranium. The column assembly and shielding are encased in a plastic container that is covered with a plastic elution hood. The elution hood has an opening for the column assembly double inlet needles and an opening for the single outlet needle. The needles accommodate the sterile eluant vials that contain 0.9% Sodium Chloride Injection and sterile evacuated collection vials. A sterile vial containing a bacteriostat is supplied with the generator for the customer to aseptically seal the outlet needle after each elution. 

This terminally sterilized generator provides a closed system for the production of sterile metastable technetium Tc-99m, which is produced by the decay of molybdenum Mo-99. Incorporated between the column outlet and the collection vial is a sterile 0.22 micrometer filter. Sterile, non-pyrogenic isotonic solutions of Sodium Pertechnetate Tc 99m Injection in 0.9% Sodium Chloride Injection can be obtained conveniently by periodic aseptic elution of the generator. These solutions should be clear, colorless, and free from any particulate matter. The Sodium Pertechnetate Tc 99m Injection is suitable for intravenous injection and direct instillation.   


The carrier-free solution may be used as is, or diluted to the proper concentration. Over the life of the generator, an elution will contain an amount of technetium Tc-99m in direct proportion to the quantity of Mo-99 decay since the previous elution of the generator. The quantity of Tc-99m in the eluate is determined by quantity of Mo-99 on the column, and the elapsed time between elutions.   


Each eluate of the generator should not contain more than the USP limit of 0.15 kilobecquerel molybdenum Mo-99 per megabecquerel technetium Tc-99m (0.15 microcurie Mo-99 per millicurie Tc-99m) per administered dose at the time of administration and an aluminum ion concentration of not more than 10 micrograms per milliliter of the generator eluate, both of which must be determined by the user before administration.

Since the eluate does not contain an antimicrobial agent, it should not be used after 12 hours from the time of generator elution.
Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
PURPOSE:To obtain the titled stable composition, by incorporating an oily mixture consisting of a medium-chain triglyceride and sucrose isobutylacetate or polyglycerol acetate with an aqueous solution of a natural gum substance, and emulsifying the resultant mixture. CONSTITUTION:20pts.wt. or less oily mixture consisting of 40-99.9wt% medium- chain triglyceride, e.g. triglyceride of caproic acid, caprylic acid and capric acid, and 0.1-60wt% sucrose isobutylacetate or polyglycerol acetate is incorporated with >=80pts.wt. 40wt% or less aqueous solution of a natural gum substance, e.g. gum arabic, xanthan gum or tragacanth gum, to give an emulsified composition having excellent emulsion stability and good flavor. The resultant emulsified composition can be lightly taken as a drink at any time and is excellent for portable use.
The invention relates to a nasal spray composition for treating migraine and a preparation method thereof. The nasal spray composition is prepared from the following raw materials in parts by weight: 100 to 150 parts of ligusticum wallichii, 10 to 50 parts of asarum sieboldii, 100 to 150 parts of radix angelicae and 0.2 to 1 part of borneol. The nasal spray composition is characterized in that the ligusticum wallichii, the asarum sieboldii and the radix angelicae are prepared into essential oil and/or aromatic water; and the borneol is prepared into a borneol solution. In addition, the nasal spray composition further comprises a solubilizer with the volume ratio of 4.5% to 6%, a corrosion remover with the volume ratio of 0.1% to 0.2% and the balance of water. At present, the nasal spray preparation special for treating the migraine is not provided in clinical; and the oral administration is adopted in the most of time. The medicine administration through the nasal cavity can directly effect on a diseased position without passing through gastrointestinal tracts. In general, the required dosage of the nasal spray composition is only about one tenth or one fifteenth of that of an oral medicine; and the first-pass effect of the oral medicine is avoided. The nasal spray composition is high in bioavailability and convenient in medicine administration. According to the preparation method, by selecting the effective active medicine ingredients and improving the medicine concentration, the nasal spray which is convenient to use and carry is prepared.
FIELD: veterinary science, microbiology. SUBSTANCE: invention relates to specific prophylaxis of sicknesses in animals. Inactivated vaccine against salmonellosis in calves has mixture of antigens of virulent immunogenic strains of serovaras Salmonella dublin, Salmonella typhimurium prepared in physiological solution, adjuvant and 0.4-0.5% (vol./vol.) of formalin as preserving agent. As antigens of serovara of Salmonella dublin vaccine has the strain Salmonella dublin N 1449. As antigen of serovara of Salmonella typhimurium vaccine has the strain Salmonella typhimurium N 159. As immunostimulating agent vaccine has suspension of cells Rhodococcus equi N 2 prepared in physiological solution. As adjuvant vaccine has oil-lanoline mixture. Vaccine provides the development of expressing long immunity in calf body. EFFECT: enhanced effectiveness of vaccine, decreased dose and dosing. 3 ex
This is a single arm and single-center tolerability study of high dose HCQ therapy in outpatient adult participants with mild COVID-19. In vitro studies have shown antiviral effects of HCQ against SARS Cov-2, but the clinical outcomes in the disease have been variable. The hypothesis is that targeting high risk patients earlier in the disease course and with a higher dose regimen are both required to see improvement in disease outcome measures in COVID-19. This study aims to prove the tolerability of high dose HCQ in this setting.

Patients are selected based on the identification of risk factors associated with more severe disease outcomes. Investigators will enroll twenty patients and perform a detailed Tele-health interview to ensure they meet eligibility criteria and provide informed consent. 1200 mg hydroxychloroquine daily will be prescribed, in divided doses.The subjects will be required to monitor their temperatures twice daily and a daily telephone call with an investigator will review symptoms of disease and potential side effects of the drug. Subjects can discontinue the medication after five days if they no longer have fever, or take the medication for up to ten days if required for fever resolution.
Participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 1, followed by a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A).
Dysregulation of monoaminergic networks might have a role in the pathogenesis of fatigue in multiple sclerosis (MS). We investigated longitudinal changes of resting state (RS) functional connectivity (FC) in monoaminergic networks and their association with the development of fatigue in MS. Eighty-nine MS patients and 49 age- and sex-matched healthy controls (HC) underwent neurological, fatigue, and RS functional MRI assessment at baseline and after a median follow-up of 1.3 years (interquartile range = 1.01-2.01 years). Monoaminergic-related RS FC was estimated with an independent component analysis constrained to PET atlases for dopamine (DA), noradrenaline (NA), and serotonin (5-HT) transporters. At baseline, 24 (27%) MS patients were fatigued (F) and 65 were not fatigued (NF). Of these, 22 (34%) developed fatigue (DEV-FAT) at follow-up and 43 remained not fatigued (NO-FAT). At baseline, F-MS patients showed increased monoaminergic-related RS FC in the caudate nucleus vs NF-MS and in the hippocampal, postcentral, temporal, and occipital cortices vs NF-MS and HC. Moreover, F-MS patients exhibited decreased RS FC in the frontal cortex vs NF-MS and HC, and in the thalamus vs NF-MS. During the follow-up, no RS FC changes were observed in HC. NO-FAT patients showed limited DA-related RS FC modifications, whereas DEV-FAT MS patients showed increased DA-related RS FC in the left hippocampus, significant at time-by-group interaction analysis. In the NA-related network, NO-FAT patients showed decreased RS FC over time in the left superior frontal gyrus. This region showed increased RS FC in both DEV-FAT and F-MS patients; this divergent behavior was significant at time-by-group interaction analysis. Finally, DEV-FAT MS patients presented increased 5-HT-related RS FC in the angular and middle occipital gyri, while this latter region showed decreased 5-HT-related RS FC during the follow-up in F-MS patients. In MS patients, distinct patterns of alterations were observed in monoaminergic networks based on their fatigue status. Fatigue was closely linked to specific changes in the basal ganglia and hippocampal, superior frontal, and middle occipital cortices.
BACKGROUND: Chronic kidney disease (CKD) is a risk factor for embolic stroke, and many nonvalvular atrial fibrillation (NVAF) patients have concomitant CKD. Anticoagulation therapy can be challenging in CKD due to increased bleeding risk, and left atrial appendage occlusion (LAAO) may be a promising alternative.
OBJECTIVE: This systematic review aimed to consolidate current evidence on the safety and effectiveness of transcatheter LAAO in patients with CKD and end-stage renal disease (ESRD).
METHODS: Medline, Cochrane, and Embase databases were searched from inception to September 2, 2022. We conducted a meta-analysis if an outcome was evaluated in at least two similar studies.
RESULTS: We included 15 studies with 77,780 total patients. Of the 15 studies, 11 had a cohort design (five prospective and six retrospective), and four were case series. Patients with CKD were older and had a higher prevalence of comorbidities than non-CKD patients. The two groups did not differ in procedural failure rate, vascular complications, or pericardial tamponade. CKD patients exhibited higher odds of in-hospital acute kidney injury (AKI) and bleeding, longer-term bleeding, and mortality than those without CKD. The risk of in-hospital and longer-term cardioembolic events was similar between CKD and non-CKD populations (odds ratio = 1.01 [95% CI 0.70-1.15] and 1.05 [95% CI 0.55-2.00], respectively). Patients with ESRD had higher odds of in-hospital mortality and cardioembolic events than non-ESRD patients, with no differences in risk of pericardial tamponade.
CONCLUSIONS: Based on observational studies, LAAO may be an effective option to prevent cardioembolic events in CKD. However, CKD patients may have higher odds of AKI and in-hospital and long-term bleeding and mortality. The adverse clinical outcomes observed in CKD patients may be attributed to this population's high burden of comorbidities, especially among those with ERSD, rather than the LAAO procedure itself. To ensure maximum clinical benefit, careful patient selection, management, and surveillance involving multidisciplinary teams are essential for CKD patients undergoing LAAO.
A method, and a compound for facilitating it, that enhances night vision by dispersing a luminescent to provide low-intensity area illumination. Luminescents may include naturally occurring bioluminescents (visible spectrum) or man-made, preferably non-toxic, chemical-based luminescents (also termed chemiluminescents), the latter available for use in either the visible or IR spectrum. It may be applied locally to a surface or remotely by means of a delivery system. Preferably, select luminescents are dispersed as an aerosol to contact targeted surfaces. These luminescents may be used in spaces otherwise difficult to image with night vision equipment. Specifically provided is a method for viewing a target under low ambient light conditions comprising dispersing a luminescent material on surfaces in a dark space to provide a low-level, spatially broad, source of supplemental scene illumination, and viewing the target with image enhancing devices that are otherwise marginally useful without the presence of the luminescent material.
The invention provides acid sensitive cation channel proteins which are capable of reversibly mediating (i) a rapid, and (ii) a sustained cation current, particularly the SPASIC protein or variants (e.g. homologues or fragments) thereof. Also provided are nucleic acids encoding these, or which have utility in probing, amplifying or down-regulating these. Methods of providing the proteins and nucleic acids are disclosed, as are vectors, host cells, and organisms utilising them, and antibodies. Also disclosed are methods of influencing the electrophysiological and/or pharmacological properties of a cell (e.g. by way of therapy) based on manipulation of the proteins or nucleic acids, and methods for screening for substances having ion-channel modulating activity (which may be potential analgesics; neuromodulatory agents; anti-inflammatory agents; agents that regulate neurotransmitter release or neuronal excitability).
This utility model relates to a formulation for fungi-infected skin, a mixture of extracts from Origanum vulgare, Vitex negundo, Persea americana, Ehretia microphylla, Blumea balsamifera, Piper betle, and Coconut (Cocos nucifera) oil and Petroleum jelly as the base ingredients. Active ingredients from the leaves' extracts work in synergy combating fungal diseases like ringworm (buni), tinea versicolor/ (tinea flava /an-an), eczema, scabies (galis-aso), athlete's foot (alipunga), nail fungus, jock itch, vaginal yeast infection and mouth thrust. The anti-bacterial, antimicrobial, anti-inflammatory, antioxidant, analgesic properties of the ingredients address problems in cases of severe fungal skin infection and It gives instant relief to itchiness and helps subside swelling, blistering and scaling of skin associated with skin diseases due to the presence of Candida albican. The formulation is utilized by regular application to fungi-infected skin ointment, once a day for mild cases like rashes and 3 times a day in severe and contagious condition, applying after removing the dead skin with the use of sanitary tissue paper or cotton. Formulation has to be applied until fungi and mites are exterminated and relief is attained. The formulation for fungi-infected skin has a powerful potencies within the product was tested among 100 respondents on the onslaught of typhoon Urduja in the Philippines, year 2017. The respondents were suffering from skin diseases due to exposure to a flood water. According to the result of the study, 100 pcnt of the respondents were happy experiencing relief from the distress cause by the skin diseases. The affected skin becomes healthy and gain self-confidence once more.
FIELD: medicine.SUBSTANCE: group of inventions relates to the field of making dental prostheses. Disclosed is a kit for making dental prostheses, comprising a dental workpiece for milling, comprising porous zirconium dioxide material, and a coloring solution for coloring porous zirconium dioxide material. Porous zirconium dioxide material contains Zr oxide in terms of ZrO: from 80 wt. % to 97 wt. %, Al oxide in terms of AlO: from 0 wt. % to 0.15 wt. %, Y-oxide in terms of YO: from 1 wt. % to 10 wt. %, Bi oxide in terms of BiO: from 0.01 wt. % to 0.2 wt. %, wherein porous zirconium dioxide material does not contain Fe in terms of FeOin amount of more than 0.01 wt. %, wherein values in wt. % are given with reference to porous zirconium dioxide material weight. Coloring solution contains at least one solvent, at least one coloring agent containing metal ions selected from ions Tb, Er, Pr, Mn, or their combination, wherein the solution does not contain Fe ions in amount of more than 0.01 wt. %, wherein the solution does not contain Bi ions in amount of more than 0.01 wt. %, wherein values in wt. % are given with respect to the weight of the coloring solution. What is also presented is a method for making a dental prosthesis, which comprises the following steps: providing said dental workpiece for milling, which contains porous zirconium dioxide material, milling an article from porous zirconium dioxide material, wherein the article has the shape of a dental prosthesis with outer and inner surfaces, providing said coloring solution, application of solution for coloring on at least part of surface of article, having shape of dental prosthesis.EFFECT: by simultaneous use of said dental billet for milling, containing bismuth, and said solution for coloring, substantially free of iron, dentures can be made with almost all required tooth colors.14 cl, 2 ex
PURPOSE:To obtain a bathing agent, containing glycerol diester of fatty acids as an oily ingredient and remarkably improved in skin care effects. CONSTITUTION:The objective substance obtained by blending 0.1-50 pts.wt. glycerol diester of fatty acids as an oily ingredient in raw materials for a bathing agent and preparing the bathing agent. The above-mentioned agent can be prepared in the form of powder, granule, tablet, liquid, etc., and used by pouring into bath water in bathing. In the bathing, the amount thereof used at a time is determined so as to provide 10-500ppm concentration of the oily ingredient in the bath water. The glycerol diester of the fatty acids is obtained by separating and purifying glycerol ester of fatty acids prepared by a normal method, such as esterification of glycerol with the fatty acids, through molecular distillation, extraction with a solvent, etc., and glycerol diesters of 2- ethylhexanoic acid, etc., are exemplified.
There is provided genetically engineered protein having human ChE activity, and more particularly the activity of human AChE or human pseudo-ChE. There are provided DNA sequences encoding such proteins, and more specifically DNA sequences comprising the entire coding region for encoding such complete proteins, and DNA expression vectors comprising such sequences. There is provided DNA, which has been joined outside living cells, capable of infecting culturable cells, to be maintained therein and in progenies thereof which is adapted to encode such active proteins. The invention further provides culturable cells infected with recombinant DNA defined above, and to purified proteins having human ChE activity produced by such cells. There are further provided antibodies interacting with human AChE and pseudo-ChE and assays based on the use of such antibodies. The invention also provides compositions counteracting the effects of succinylcholine and of OP compounds. containing as active ingredient an effective dosage of proteins defined above.